Skip to search boxSkip to navigationSkip to main content

Update on pharmacologic therapy for pulmonary embolism

  • Prakash Harikrishnan
    ,
  • Chandrasekar Palaniswamy
    ,
  • Wilbert S. Aronow(corresponding author)
*Corresponding author for this work
  • New York Medical College
Scholary Output:
Contribution to journal
Review article
Peer-review

Abstract

Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 159-169 (11 pages)

Journal (Volume, Issue Number)

Journal of Cardiovascular Pharmacology and Therapeutics (Volume 19, Issue 2)

Publication milestones

  • Published - 03/2014

Publication status

Published - 03/2014

ISSN

1074-2484

Publication IDs

  • Scopus: 84894448506
  • PubMed: 24177334

Publication metrics

Metrics

SciVal
FWCI
0.24
SciVal
Author count
3
SciVal
citations
4
SciVal
Paper percentile
50
Fractional count
1
Fractional count
0.33
Fractional count
2
Fractional count
0.67
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Usage
29
Citation count
5
Captures
39